Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EP 0017

Next Previous
Drug Profile

EP 0017

Alternative Names: EP-0017; SRB-22

Latest Information Update: 28 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SunRock Biopharma
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Jun 2026 No recent reports of development identified for preclinical development in Solid-tumours in Spain (Parenteral)
  • 12 Jun 2022 SunRock has patent protection for HER3 targeted antibodies (Sunrock Biopharma website, May 2022)
  • 31 May 2022 Ellipses pharma and SunRock biopharma entered into a licensing agreement for SRB 22

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top